ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial Non-Comparative, Two-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects after Failure of Autologous tem Cell Transplant (ASCT)Revised Protocol 01 incorporating Amendment 03
EudraCT number 2014-001509-42
Protocol number CA209-205
Sponsor Bristol-Myers Squibb International Corporation,Chaussée de la Hulpe 185,Brussels,1170
Indications Hemato-oncology
Diagnosis Hodgkin Lymphoma
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Male
Female
Patients
Year of receiving the request to Institute (SÚKL) 2014
Date of approval by Institute (SÚKL) 12.9.2014
Date of approval by EC 16.10.2014
Date of initiation CT in ČR 17.12.2014
Date of ending CT in ČR
Notice
Sites Vseobecna fakultni nemocnice v Praze,I. interni klinika - klinika hematologie 1. LF UK a VFN v Praze,U Nemocnice 2,Praha 2,128 08

‹‹ Back to list